Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Talen Energy | ASE Technology Holding | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K grounds a real but bounded advantage. Susquehanna produced about 17 TWh in 2025 at an all-in cost of about $27/MWh, and up to 1,920 MW of it is contracted to AWS under a long-term, fixed-price PPA through 2042 'at anticipated premium prices', with deliveries expected to ramp to full volume no later than 2032. The moat is narrow rather than wide because, outside its contracts, the fleet sells into competitive wholesale markets, and the 10-K says that 'unlike regulated utilities, we are not assured of any rate of return on capital investments through a regulated rate structure'. It also concedes that competitors 'may have advantages over us through access to greater resources, newer generation facilities, lower costs, or more experience'. The advantage is also concentrated: Susquehanna has typically been about half of total annual generation. | narrow The FY2025 20-F argues ASEH out-competes IDM in-house lines because serving "a large base of customers across a wide range of products" lets it "reduce costs and shorten production cycles through high-capacity utilization and process expertise" and gives its equipment "a longer useful life" — a real but bounded edge, since the same filing calls the global packaging and testing market "highly competitive", notes "most of our customers obtain services from more than one source", flags foundry encroachment ("TSMC has offered advanced packaging technologies such as integrated fan-out"), and warns that "some of our competitors may have superior financial, marketing, manufacturing, research and development and technological resources than we do", offering P.R.C. government support of its domestic semiconductor companies as the example. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | cost scale The 10-K says Talen's ability to compete 'is affected primarily by electricity prices, fuel prices, the relative cost of electric generation, and the reliability and availability of generation assets'. The edge it cites is low-cost baseload supply: Susquehanna, the seventh-largest U.S. nuclear plant, produced power at an all-in cost of about $27/MWh in 2025, under NRC licences that expire in 2042 and 2044. The 10-K says natural gas facilities 'often serve as the marginal, price-setting generating units' and that energy margin is influenced by the relationship between electricity and natural gas prices, so a low-cost nuclear unit earns the gap between market price and its own cost. The AWS adjacency is a contract rather than a fleet-wide switching cost, and network effects and IP do not apply. | cost scale The advantage the 20-F actually claims is unit economics from volume, not lock-in: specialization and "economies of scale by providing services to a large base of customers", high capacity utilization spreading "relatively high fixed costs", and equipment that lasts longer because of the breadth of the order book. Capital intensity reinforces it — the filing says "semiconductor businesses are capital intensive and require significant investment in expensive equipment manufactured by a limited number of vendors", with the equipment market itself "characterized by intense demand, limited supply, and long delivery cycles". | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | at parity Talen calls itself 'a leading independent power producer', but its merchant output is undifferentiated. The 10-K says it sells into PJM capacity auctions and day-ahead and real-time markets against 'other non-utility generators, regulated utilities and their competitive subsidiaries, industrial companies, financial institutions, and other energy marketers', and that some rivals may have greater resources, newer plants or lower costs. Susquehanna's rank as the seventh-largest U.S. nuclear facility shows scale, not market leadership. | co leader The 20-F calls ASEH "a leading provider of semiconductor manufacturing services in assembly and testing" and "a market leader in SiP technologies from design to assembly with high-volume manufacturing", and says it has "established ourselves as a leader through the successful introduction of leading-edge advanced packaging solutions, which have played a pivotal role in bringing advanced ASIC and HBM products to the marketplace" — but the hedged "we believe we are among the leaders in such packaging processes and technologies", alongside named consolidating rivals (Jiangsu Changjiang Electronics Technology/STATS ChipPAC, Amkor/J-Devices, Tianshui Huatian Technology/Unisem) and TSMC's InFO, describes shared rather than sole leadership. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate Pricing power is mixed and sits in the AWS contract. The AWS PPA is fixed-price 'at anticipated premium prices' through 2042, and the 10-K says such large-load contracts 'can lock in meaningful premiums'. The Brandon Shores and H.A. Wagner RMR agreements provide FERC-approved annual fixed-cost payments of $145 million and $35 million from June 1, 2025, each including a performance hold-back, and FERC's approval is under appeal by the Maryland Office of People's Counsel; they give revenue certainty rather than pricing power. The merchant remainder takes market prices. The 10-K says gas units 'often serve as the marginal, price-setting generating units', and the PJM auction imposed a capacity price collar with an approximate minimum and maximum of $175/MWd and $325/MWd for the 2026/2027 and 2027/2028 auctions. In the 2027/2028 auction Talen cleared 8,745 MW at $333.44/MWd. | weak The 20-F states the industry has "a general trend toward declining prices for products and services of a given technology over time" and that ASEH's own "average selling prices of our packaging and testing services have experienced sharp declines" under "intense price competition". FY2025 consolidated gross margin was 17.7% (up from 16.3%), and management attributes the gain to "higher packaging and testing revenue mix and higher factory utilization" rather than price; the EMS half earned a 9.2% gross margin on raw-material costs equal to 78.7% of EMS revenue, and the five largest customers supplied 46.5% of 2025 operating revenues. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | Talen's advantage comes from one contracted asset. It owns 90% of the 2.5 GW Susquehanna nuclear plant, which produced about 17 TWh in 2025 at about $27/MWh all-in, and it has agreed to supply the adjacent AWS data campus with up to 1,920 MW under a fixed-price PPA through 2042. The rest of its roughly 13.1 GW fleet at the 10-K date (a total that includes its 2.2 GW nuclear share) includes newly acquired H-class combined-cycle gas plants, intermediate and peaking units, the Brandon Shores and H.A. Wagner units kept running under FERC-approved RMR agreements, and about 800 MW of minority interests in three coal-fired plants. Apart from the RMR units, that fleet sells capacity and energy mainly into competitive PJM markets through capacity auctions, spot markets and futures contracts, and the 10-K notes that, 'unlike regulated utilities, we are not assured of any rate of return on capital investments through a regulated rate structure'. The 10-K's 'Talen flywheel' strategy is to repeat the AWS model with other large-load buyers. Until more of the fleet is contracted, the moat stays narrow and concentrated in Susquehanna. | ASEH sells turnkey assembly and test at a scale most captive IDM lines cannot match: the 20-F says it is "involved in all stages of the semiconductor manufacturing process except circuit design and wafer fabrication", and leans on Taiwan, "currently the largest center for outsourced semiconductor manufacturing in the world", plus a "strategic alliance with TSMC", to sit next to the foundries its customers already use. The durable part is cost position from utilization, not customer capture — the filing concedes customers multi-source and that foundries are moving into advanced packaging from above. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | Supplies nuclear power from Susquehanna to Amazon's adjacent AWS data campus, and sells capacity and energy into the PJM grid. | Back-end contractor to the AI silicon chain: the 20-F ties its FOCoS, FOCoS-Bridge and 2.5D/3D lines to "ASICs and HBM for HPC, networking, server and AI/ML applications" and "AI accelerators for AI training", and warns that a slowdown in AI demand would leave "lower utilization rates for our specialized equipment". | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |